Angelini Pharma strikes $4.1B deal for Catalyst

Angelini Pharma said on May 7, 2026, that it has agreed to acquire Catalyst Pharmaceuticals in an all-cash deal valued at about $4.1 billion, or $31.50 per share. Both companies’ boards unanimously approved the transaction, which would bring Catalyst’s rare neurology portfolio, including FIRDAPSE, AGAMREE, and the U.S. rights to FYCOMPA, under Angelini and give the Italian company a direct commercial foothold in the U.S. market. The companies said the deal is expected to close in the third quarter of 2026, subject to Catalyst shareholder approval, antitrust review, and other customary conditions. (ir.catalystpharma.com)

Why it matters: For veterinary professionals, this is mainly a signal about where specialty pharma capital is moving: toward rare disease, neurology, and established commercial assets with reimbursement potential. While the products involved are human medicines, the transaction reflects continued consolidation around brain health and orphan-drug franchises, an area that can influence partnership activity, pricing strategy, talent movement, and investor expectations across adjacent animal health and specialty therapeutics markets. Catalyst has also highlighted payer coverage, competition, and loss-of-exclusivity risk as important business factors, underscoring the commercial pressures that make scaled portfolios attractive. (sec.gov)

What to watch: Watch for Catalyst’s proxy filing, shareholder vote, Hart-Scott-Rodino clearance, and any detail on how Angelini plans to integrate Catalyst’s U.S. commercial infrastructure as the companies target a third-quarter 2026 close. (sec.gov)